AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01429506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive medical management
Description: Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
Study NCT03288389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NTFactor Lipids®
Description: Membrane Lipid Replacement with NTFactor Lipids wafers
Study NCT03288389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo wafers
Study NCT00719303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Receive dietary intervention
Study NCT00719303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compliance Monitoring
Description: Complete daily fat gram and step diaries
Study NCT02355223 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FAST
Description: See information in arm description
Study NCT01325441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Study NCT01325441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01662999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Study NCT00719303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo face-to-face and telephone counseling
Study NCT00719303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials
Study NCT00719303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo physical activity intervention
Study NCT00719303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00719303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00719303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00719303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00719303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00719303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01499147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine/ melphalan
Description: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl).
Study NCT01499147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.
Study NCT02502474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus carriage
Description: nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
Study NCT01960374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: 1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.
Study NCT03682341 — intervention group
Intervention type: GENETIC
Intervention: endometriosis
Description: patients with or without ovarian endometriosis
Study NCT03909620 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography of chest
Description: Eligible subjects will undergo a single round of LDCT screening. The LDCT will be considered as positive if a solid nodule or part-solid nodule of size ≥6 mm or non-solid nodule of size ≥20 mm is identified. Evaluation of positive nodules will be performed as per existing standard recommendations
Study NCT04504240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine 20 MG
Description: Famotidine; tablet Famotac 20mg oral form.
Study NCT04504240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine 20 MG
Description: Famotidine; tablet Famotac 20mg oral form.
Study NCT02834026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicloergometry training
Study NCT02834026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Cicloergometry training
Study NCT00820586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mononuclear bone marrow derived cells
Description: Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
Study NCT01703975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in pairs (Dyad training)
Study NCT03023956 — intervention group
Intervention type: PROCEDURE
Intervention: Locking plates were used for proximal humeral fractures.
Study NCT00614250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0657
Description: capsules once a day at bedtime
Study NCT00614250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules once a day at bedtime
Study NCT04185493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA
Description: 128-multislice CT coronary angiography and complex atherosclerotic plaque analysis with the use of CT imaging post-processing techniques.
Study NCT03950089 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography (OCT-A)
Description: Optical Coherence Tomography Angiography (OCT-A) images were acquired using an Spectral Domain Optical Coherence Tomography device (Cirrus High Definition OCT Model 5000 with Angioplex; Carl Zeiss Meditec, Dublin, California, USA). With an acquisition speed of 68,000 A-Scan per second, the OCT Microangiography Complex algorithm provided OCT-A information for three-dimensional (3D) flow reconstruction. At each visit, each subject underwent a 3 x 3 millimeter (mm) macular 3D cube acquisition in both eyes. FastTrac continuous eye tracking technology was employed to control for eye movements and minimize motion artefacts.
Study NCT03968172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EBBC programme
Description: Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In the programme, techniques and exercises will be taught in sequentially active interactive learning units (simulated dialogues) and followed-up with email and SMS reminders in the second study year. The following topics will be focused on:~1. Diagnosis and disease progression~2. Support in disease processing~3. Techniques for coping with stress and depressive symptoms as well as developing positive emotions~4. Optimisation of dietary behaviour~5. Optimisation of physical activity behaviour~6. Sleep hygiene and methods for dealing with insomnia.~The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules.
Study NCT03968172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group programme
Description: Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics:~1. Disease progression~2. Invisible symptoms of multiple sclerosis~3. Symptomatic therapy~4. Immunotherapy decision support~5. Coping strategies~6. Autonomy~7. Fatigue~8. Quality of life~9. Physical activity~10. Nutritional behaviour~In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme.
Study NCT00958334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proellex®
Description: 25 mg daily (two 12.5 mg capsules)
Study NCT00958334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex®
Description: 25 mg daily (two 12.5 mg capsules)
Study NCT01095315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lateral positioning
Description: the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
Study NCT02816450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water Intake
Study NCT00247195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Congruent Assessment and Treatment
Description: Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
Study NCT00247195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally Congruent Assessment and Treatment
Description: Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
Study NCT00144534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA (Tocilizumab)
Description: 8mg/kg/4 weeks
Study NCT03251430 — intervention group
Intervention type: PROCEDURE
Intervention: gastrectomy
Description: Distal gastrectomy, Total gastrectomy
Study NCT01971060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgery utilizing V-Loc suture
Description: V-Loc suture will be utilized in the repair of the uterus following removal of fibroid tumors. a second look laparoscopy will be done on all subjects to evaluate scar tissue formation.
Study NCT02219620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music, Imagery, Movement
Description: Implementation of music, art and imagery activation, and movement in group modality
Study NCT02219620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Control
Description: social conversational group facilitated by care counselor
Study NCT05181566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement arthroplasty using modular dual mobility cup
Description: In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
Study NCT05040529 — intervention group
Intervention type: PROCEDURE
Intervention: pure laparoscopic donor hepatectomy
Description: pure laparoscopic donor hepatectomy: patients who underwent pure laparoscopic right or right extended hepatectomy for liver donation at gangnam severance hospital
Study NCT05040529 — intervention group
Intervention type: PROCEDURE
Intervention: conventional open donor hepatectomy
Description: conventional open donor hepatectomy: patients who underwent conventional right or right extended hepatectomy for liver donation at gangnam severance hospital
Study NCT01783665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Study NCT01783665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercise program
Study NCT02205450 — intervention group
Intervention type: DRUG
Intervention: Recombinant Somatropin
Study NCT02628587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic clopidogrel
Description: Comparison of different brands of clopidogrel:~\*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3.
Study NCT02628587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patent clopidogrel
Description: Comparison of different brands of clopidogrel:~\*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3.
Study NCT02554305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fusion oxygenation system
Description: The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
Study NCT02554305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Affinity oxygenation system
Description: The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
Study NCT04321343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL065
Description: PXL065 oral tablet
Study NCT04321343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study NCT01323296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
Study NCT00998738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Gluconate
Description: Given IV
Study NCT00998738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Given IV
Study NCT00998738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT00998738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00998738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00998738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00998738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00998738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV
Study NCT00998738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixabepilone
Description: Given IV
Study NCT01960010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIM-D3 Ophthalmic Solution
Description: 1% MIM-D3 dosed BID
Study NCT01960010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle dosed BID
Study NCT00765765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Dose escalation from 200 mg po qd to 200 mg po bid.
Study NCT00765765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
Study NCT01835444 — intervention group
Intervention type: OTHER
Intervention: PA/MD model
Description: Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
Study NCT02643550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monalizumab
Study NCT02643550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT02643550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD(L)1
Study NCT01262430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OtisMed
Description: OtisMed Custom-fit Shapematching Guides
Study NCT01262430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computer Assisted Surgery (CAS)
Description: Stryker Navigation System
Study NCT03880565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation
Description: Early use of ECMO
Study NCT03880565 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Advanced Cardiac Life Support (ACLS) Resuscitation
Description: Standard life support resuscitation
Study NCT01567514 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glass ionomer cement lining
Description: Resin-modified glass ionomer lining
Study NCT01567514 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Glass ionomer cement lining
Description: Resin-modified glass ionomer lining
Study NCT04026425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two-day cardiopulmonary exercise test
Description: A series of two cardiopulmonary exercise tests (CPETs) performed over two days. Participants will perform a CPET and then will return approximately 24 hours later to perform the second CPET. The CPET begins with 3 minutes of seated rest followed by cycling during incremental workloads which increases 15 watts throughout each minute of exercise. The participant will cycle until volitional exhaustion and/or the participant and/or test administrator determines to stop the test. Actual exercise time usually varies between 8-10 minutes.
Study NCT04026425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-day cardiopulmonary exercise test
Description: A series of two cardiopulmonary exercise tests (CPETs) performed over two days. Participants will perform a CPET and then will return approximately 24 hours later to perform the second CPET. The CPET begins with 3 minutes of seated rest followed by cycling during incremental workloads which increases 15 watts throughout each minute of exercise. The participant will cycle until volitional exhaustion and/or the participant and/or test administrator determines to stop the test. Actual exercise time usually varies between 8-10 minutes.
Study NCT02232347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02232347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Study NCT01286350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FL3X: Flexible Lifestyle Empowering Change
Description: The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.
Study NCT01902069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phospholean
Description: Phospholean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).~PhosphoLean® 40P is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) regulations of the US FDA (1994).
Study NCT02733042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered as an IV infusion (250 mL) over approximately 1 hour in duration
Study NCT01902069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of rice flour
Study NCT01809067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender aromatherapy inhalers
Description: Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
Study NCT02684175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote CI Counseling
Description: The remote setup includes a 500 series teleconference audio and video live set-up. The teleconference set-up will be situated on a telemedicine cart and placed within the sound-proof booth at the testing site (UK ENT practice in Morehead, KY). The audiologist will deliver the session remotely.
Study NCT02684175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person CI Counseling
Description: The standard face-to-face counseling that will occur between the participant and audiologist is the standard of care. No technology will be used. The audiologist will deliver the session face-to-face with the participant in the same room (standard practice).
Study NCT02733042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally
Study NCT02733042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered by intravenous infusion
Study NCT02733042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered orally
Study NCT02733042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Administered as a 30-minute intravenous infusion
Study NCT01952301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xenogeneic Collagen Matrix
Description: A type I and III porcine collagen matrix, as cleared by FDA (K012423)
Study NCT01952301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: Autogenous, full-thickness soft tissue graft harvested from patient's palate.